Astra and Daiichi beat Gilead to the punch, at least in one setting.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
Duality takes its Adam9-targeting conjugate into the clinic.
It’s a new term for biotech and its investors.
Pumitamig is the latest to be tested in first-line disease.
China's Harmoni-A trial hits on overall survival, but hopes for a global phase 3 seem optimistic.
Qilu moves its GPRC5D T-cell engager into phase 3, but trispecifics set the new pace.
After Dren secured buy-in from Novartis, LTZ becomes a clinical player.